TABLE 3.
Clinical features of recruited patients with CD8+/pentamer+ cells directly detectable ex vivo according to TRAF1 expressiona
| Characteristic | Value(s) for patients with: |
P value | |
|---|---|---|---|
| TRAF1low (n = 19) | TRAF1dim (n = 19) | ||
| % of patients with PI/RI | 64/36 | 15/85 | 0.003b |
| Median (IQR) age (yr) | 53 (11) | 57 (10) | NSc |
| % of male patients | 68 | 58 | NSb |
| Median (IQR) duration of infection (yr) | 34 (11) | 32 (5) | NSc |
| Median (IQR) viral load (IU · ml−1, log scale) | 5.9 (6.6) | UDL | 0.003c |
| Mean (SD) ALT concn (IU · ml−1) | 64 (76) | 35 (9) | 0.136c |
| % of patients with significant fibrosis (F3-F4) | 57 | 42 | NSb |
| Median (IQR) liver fibrosis progression rate (Metavir score [unit · year−1]) | 0.074 (0.07) | 0.069 (0.06) | NSc |
| % of patients who were slow fibrosers | 45 | 36 | NSb |
a
ALT, alanine aminotransferase; IQR, interquartile range; NS, nonsignificant; PI, persistent infection; RI, resolved infection after treatment; UDL, under the detection limit.
b
Determined by the chi-square test.
c
Determined by the Mann-Whitney U test.